Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glucocorticoid-induced transcript 1 protein (GLCCI1)
- Target
- GLCCI1
- Molecular classification
- Other (non-classical protein; not classified as receptor, enzyme, transporter, ion channel, transcription factor, histone modifier), Intracellular protein
01
Overview
Glucocorticoid-induced transcript 1 protein (GLCCI1) is an intracellular protein encoded by the GLCCI1 gene, highly expressed in glomerular podocytes and induced by glucocorticoids. GLCCI1 plays a role in the development and maintenance of podocyte foot processes, crucial for the glomerular filtration barrier. It also acts as an anti-apoptotic mediator in thymic T cells during glucocorticoid exposure. Genetic variants in GLCCI1 have been associated with variability in the response to inhaled glucocorticoid therapy in asthma patients. GLCCI1 is not classified as a classical therapeutic drug target but may serve as a biomarker for kidney health and glucocorticoid therapy responsiveness. Its broader biological function and mechanistic involvement in disease remain to be fully characterized
- Other names
- GIG18FAM117CTSSN1GCTRglucocorticoid-induced transcript 1 proteinglucocorticoid induced transcript 1Fam117C
02
Mechanism of action
Modulation of apoptosis in thymic T cells via anti-apoptotic activity induced by glucocorticoid-receptor signaling. Possible involvement in podocyte foot process formation and maintenance through transcriptional regulation and PI3K pathway association.
03
Biological functions
Regulation of podocyte development and maintenance, important for glomerular filtration barrier integrityAnti-apoptotic mediator in thymic T cells under glucocorticoid regulationEarly marker of glucocorticoid-induced apoptosis in immune cells
04
Disease associations
Glomerular diseases (including nephrotic syndrome, proteinuria, diabetic nephropathy)Response to glucocorticoid therapy, particularly in asthma (genetic variants associated with differential drug response)Potential involvement in certain cancers via fusion proteins (e.g., GLCCI1-BRAF and ST3GAL3-GLCCI1 fusions)
05
Safety considerations
No direct safety concerns specific to GLCCI1 modulation currently knownPotential therapeutic challenges include poorly understood function and the risk of off-target effects given the protein’s expression in multiple tissues
06
Interacting drugs
Indirect interaction with glucocorticoids (e.g., dexamethasone), as GLCCI1 is induced by glucocorticoid treatment
1 more in the full profile.
07
Biomarkers
Genetic polymorphisms in GLCCI1 (notably rs37973) correlate with reduced improvement in lung function after inhaled glucocorticoid therapy in asthma patients (serving as a pharmacogenomics biomarker for therapy response)GLCCI1 levels as marker of podocyte health and integrity in kidney disease models
Beyond the preview
Go deeper on Glucocorticoid-induced transcript 1 protein (GLCCI1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Glucocorticoid-induced transcript 1 protein (GLCCI1).